Answers are grounded in this paper and cite their sources.
High LAG-3 and PD-1 levels significantly inhibit CD8⁺ T cell function, resulting in weakened ability to kill tumor cells. Combined LAG-3 and PD-1 blockade can restore CD8⁺ T cell function and provides a potential avenue for development of personalized cellular immunotherapy for DLBCL.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: